—

operate a pharmacovigilance system in accordance with Article 101(1);

—

perform a regular audit of its pharmacovigilance system in accordance with Article 101(2);

—

designate a competent authority for the performance of its pharmacovigilance tasks in accordance with Article 101(3),

—

take all appropriate measures to encourage patients, doctors, pharmacists and other healthcare professionals to report suspected adverse reactions to the national competent authority in accordance with Article 102(a);

—

facilitate patient reporting through the provision of alternative reporting formats in addition to web-based formats in accordance with Article 102(b);

—

impose an obligation on a marketing authorisation holder to operate a risk management system, as referred to in Article 104(3)(c), if there are concerns about the risks affecting the risk-benefit balance of an authorised medicinal product in accordance with Article 104a(2). For the imposition of such obligation Liechtenstein will base itself on a corresponding decision of the Austrian authorities;

—

set up and maintain a national medicines web-portal which shall be linked to the European medicines web-portal in accordance with Article 106;

—

record all suspected adverse reactions that occur in its territory which are brought to its attention from healthcare professionals and patients and ensure that reports of such reactions may be submitted by means of the national medicines web-portals or by other means in accordance with Article 107a(1), and

—

submit reports in accordance with Article 107a(4).